AtomVie Global Radiopharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AtomVie Global Radiopharma Inc. - overview
Established
2021
Location
-, ON, Canada
Primary Industry
Pharmaceuticals
About
Founded in 2021 and based in Ontario, Canada, AtomVie Global Radiopharma Inc. is a spinout from the CPDC (Centre for Probe Development and Commercialization) and operates as a manufacturer and distributor of radiopharmaceuticals. In June 2023, AtomVie Global Radiopharma raised USD 90 million in series A funding led by Avego Healthcare Capital. As of 2023, Bruno Paquin is the CEO of the company.
The company provides process and method development and validation; technical, regulatory, quality, logistics; clinical and commercial manufacturing; and specialized infrastructure for radiotherapeutic development from phase 1 to the commercial marketplace. The firm specializes in radiopharmaceutical manufacturing, including radiolabeling using radioisotopes such as Lu-177, Ac-225, and I-131, as well as ligands ranging from tiny compounds to peptides to small and big antibodies. The organization plans to use the June 2023 funding to build a new facility.
Current Investors
Avego, Avego
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.atomvie.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.